The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D’Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033

Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.

Fracchiolla NS, Fattizzo B, Cortelezzi A.

Stem Cells Int. 2017;2017:6720594. doi: 10.1155/2017/6720594. Epub 2017 Aug 21

Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda – Lombardy Hematologic Network, Italy).

Fracchiolla NS, Todisco E, Bilancia A, Gandolfi S, Orofino N, Guidotti F, Mancini V, Marbello L, Assanelli A, Bernardi M, Santoro A, Cairoli R, Consonni D, Cortelezzi A.

Am J Hematol. 2017 Dec;92(12):E656-E659. doi: 10.1002/ajh.24903. Epub 2017 Oct 10

Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.

Fracchiolla NS, Iurlo A, Ferla V, Fattizzo B, Freyrie A, Reda G, Cortelezzi A.

Clin Lab. 2017 Sep 1;63(9):1513-1517

Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.

Iurlo A, Bucelli C, Cattaneo D, Orofino N, Giannotta JA, Zappa M, Gianelli U, Cortelezzi A.

Ann Hematol. 2017 Nov;96(11):1953-1954

An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review.

Orofino N, Cattaneo D, Bucelli C, Pettine L, Fabris S, Gianelli U, Fracchiolla NS, Cortelezzi A, Iurlo A.

Leuk Res Rep. 2017 Jul 27;8:7-10

Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature.

Fracchiolla NS, Sciumè M, Dambrosi F, Guidotti F, Ossola MW, Chidini G, Gianelli U, Merlo D, Cortelezzi A.

BMC Cancer. 2017 Jun 23;17(1):442

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Eder S, Canaani J, Beohou E, Labopin M, Sanz J, Arcese W, Or R, Finke J, Cortelezzi A, Beelen D, Passweg J, Socié G, Gurman G, Aljurf M, Stelljes M, Giebel S, Mohty M, Nagler A.

Am J Hematol. 2017 Oct;92(10):997-1003

‘Gardos Channelopathy’: a variant of hereditary Stomatocytosis with complex molecular regulation.

Fermo E, Bogdanova A, Petkova-Kirova P, Zaninoni A, Marcello AP, Makhro A, Hänggi P, Hertz L, Danielczok J, Vercellati C, Mirra N, Zanella A, Cortelezzi A, Barcellini W, Kaestner L, Bianchi P.

Sci Rep. 2017 May 11;7(1):1744

Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report.

Reda G, Fattizzo B, Cassin R, Flospergher E, Orofino N, Gianelli U, Barcellini W, Cortelezzi A.

Oncol Lett. 2017 Mar;13(3):1307-1310

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750

Chronic lymphocytic leukemia and prognostic models: A bridge between clinical and biological markers.

Reda G, Cassin R, Fattizzo B, Giannarelli D, Mattiello V, Barcellini W, Cortelezzi A.

Am J Hematol. 2017 Jul;92(7):E135-E137. doi: 10.1002/ajh.24755. Epub 2017 May 26

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S.

Ann Oncol. 2017 Jul 1;28(7):1547-1553

Hereditary Xerocytosis due to Mutations in PIEZO1 Gene Associated with Heterozygous Pyruvate Kinase Deficiency and Beta-Thalassemia Trait in Two Unrelated Families.

Fermo E, Vercellati C, Marcello AP, Zaninoni A, van Wijk R, Mirra N, Curcio C, Cortelezzi A, Zanella A, Barcellini W, Bianchi P.

Case Rep Hematol. 2017;2017:2769570. doi: 10.1155/2017/2769570. Epub 2017 Mar 6

Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.

Rebulla P, Vaglio S, Beccaria F, Bonfichi M, Carella A, Chiurazzi F, Coluzzi S, Cortelezzi A, Gandini G, Girelli G, Graf M, Isernia P, Marano G, Marconi M, Montemezzi R, Olivero B, Rinaldi M, Salvaneschi L, Scarpato N, Strada P, Milani S, Grazzini G.

Transfusion. 2017 May;57(5):1171-1183

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D’Errigo MG, Bova I, Zini G, Latagliata R.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3

Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers.

Sciumè M, Mattiello V, Cattaneo D, Bucelli C, Orofino N, Gandolfi L, Pettine L, Lonati S, Gianelli U, Pierini A, Cortelezzi A, Iurlo A.

Am J Hematol. 2017 Apr;92(4):E47-E48. doi: 10.1002/ajh.24656. Epub 2017 Feb 21

Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes.

Barcellini W, Fattizzo B, Zaninoni A, Valli V, Ferri V, Gianelli U, Cortelezzi A.

Am J Hematol. 2017 Mar;92(3):E26-E29. doi: 10.1002/ajh.24618. Epub 2017 Feb 3

Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.

Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W, Tagliaferri E, Andracco R, Vincenti D, Montemurro T, Mircoli L, Vitali C, Cortelezzi A.

Bone Marrow Transplant. 2017 Jan;52(1):53-58

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D’Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol. 2017 Feb 20;35(6):605-612

Biological and molecular characterization of a rare case of cutaneous Richter syndrome.

Reda G, Cassin R, Fabris S, Ciceri G, Fattizzo B, Sciumè M, Orofino N, Gianelli U, Neri A, Cortelezzi A.

Hematol Oncol. 2017 Dec;35(4):869-874

Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center.

Iurlo A, De Giuseppe R, Sciumè M, Cattaneo D, Fermo E, De Vita C, Consonni D, Maiavacca R, Bamonti F, Gianelli U, Cortelezzi A.

Hematol Oncol. 2017 Sep;35(3):335-340

The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.

Barcellini W.

Expert Rev Hematol. 2017 Jul;10(7):649-657

Recommendations regarding splenectomy in hereditary hemolytic anemias.

Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, Pignata C, Graziadei G, Pospisilova D, Rees DC, de Montalembert M, Rivella S, Gambale A, Russo R, Ribeiro L, Vives-Corrons J, Martinez PA, Kattamis A, Gulbis B, Cappellini MD, Roberts I, Tamary H; Working Study Group on Red Cells and Iron of the EHA.

Haematologica. 2017 Aug;102(8):1304-1313

Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission.

Ferla V, Zaninoni A, Fattizzo B, Fermo E, Gianelli U, Barcellini W.

Eur J Intern Med. 2017 Sep;43:e11-e14. doi: 10.1016/j.ejim.2017.04.011. Epub 2017 May 18

Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association.

Ladogana S, Maruzzi M, Samperi P, Perrotta S, Del Vecchio GC, Notarangelo LD, Farruggia P, Verzegnassi F, Masera N, Saracco P, Fasoli S, Miano M, Girelli G, Barcellini W, Zanella A, Russo G; AIHA Committee of the Italian Association of Paediatric Onco-haematology (AIEOP).

Blood Transfus. 2017 May;15(3):259-267

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.

Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, Carpenedo M, Isola M, Fanin R, Zaja F.

Eur J Haematol. 2017 Apr;98(4):371-377

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.

Trojani A, Pungolino E, Rossi G, D’Adda M, Lodola M, Camillo BD, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, Canal G, Morra E, Cairoli R.

Cancer Biomark. 2017 Dec 12;21(1):41-53

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.

Bucelli C, Cattaneo D, Ferla V, Zappa M, de Benedittis C, Soverini S, Iurlo A.

Case Rep Hematol. 2017;2017:6167345. doi: 10.1155/2017/6167345. Epub 2017 Aug 14

Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.

Gianelli U, Fiori S, Cattaneo D, Bossi A, Cortinovis I, Bonometti A, Ercoli G, Bucelli C, Orofino N, Bulfamante G, Iurlo A.

Histopathology. 2017 Dec;71(6):897-908

The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.

Gianelli U, Cattaneo D, Bossi A, Cortinovis I, Boiocchi L, Liu YC, Augello C, Bonometti A, Fiori S, Orofino N, Guidotti F, Orazi A, Iurlo A.

Mod Pathol. 2017 Jul;30(7):1043

Recovering from chronic myeloid leukemia: the patients’ perspective seen through the lens of narrative medicine.

Graffigna G, Cecchini I, Breccia M, Capochiani E, Della Seta R, Galimberti S, Melosi A, Simonetti F, Pizzuti M, Capalbo SF, Falzetti F, Mazza P, Di Renzo N, Mastrullo L, Rapezzi D, Orlandi E, Intermesoli T, Iurlo A, Pungolino E, Pacilli M.

Qual Life Res. 2017 Oct;26(10):2739-2754

Treatment of Myelofibrosis: Old and New Strategies.

Iurlo A, Cattaneo D.

Clin Med Insights Blood Disord. 2017 Mar 8;10:1179545X17695233. doi: 10.1177/1179545X17695233. eCollection 2017

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D’Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell’Adulto – Chronic Myeloid Leukemia Working Party.

Haematologica. 2017 Sep;102(9):1530-1536

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

Goel S, Paoli C, Iurlo A, Pereira A, Efficace F, Barbui T, Tefferi A, Vannucchi AM, Cervantes F.

Eur J Haematol. 2017 Jul;99(1):36-41

Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.

Iurlo A, Gianelli U, Cattaneo D, Thiele J, Orazi A.

Am J Hematol. 2017 Apr;92(4):E48-E51. doi: 10.1002/ajh.24657. Epub 2017 Feb 24

Models of Prognostication in Chronic Myelomonocytic Leukemia.

Onida F.

Curr Hematol Malig Rep. 2017 Dec;12(6):513-521

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2017 Oct 1;28(10):2517-2525

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A.

Leukemia. 2018 Feb;32(2):413-418

New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?

Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.

Expert Opin Biol Ther. 2017 Jul;17(7):821-836

Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial.

Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J, Farge D, Hawkey CJ; ASTIC trial group; European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party; European Crohn’s and Colitis Organisation.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):399-406

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T.

J Clin Oncol. 2017 Jul 1;35(19):2157-2164

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1102-1109

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2017 Jun;177(5):759-765

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762

Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.

Saraceni F, Bruno B, Lemoli RM, Meloni G, Arcese W, Falda M, Ciceri F, Alessandrino EP, Specchia G, Scimè R, Raimondi R, Bacigalupo A, Bosi A, Onida F, Rambaldi A, Bonifazi F, Olivieri A.

Bone Marrow Transplant. 2017 Jan;52(1):163-166

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537

Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening.

Platonova N, Parravicini C, Sensi C, Paoli A, Colombo M, Neri A, Eberini I, Chiaramonte R.

PLoS One. 2017 Nov 3;12(11):e0182640

Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.

Anania MC, Cetti E, Lecis D, Todoerti K, Gulino A, Mauro G, Di Marco T, Cleris L, Pagliardini S, Manenti G, Belmonte B, Tripodo C, Neri A, Greco A.

Cancer Lett. 2017 Dec 1;410:201-211

Long non-coding RNAs in B-cell malignancies: a comprehensive overview.

Nobili L, Ronchetti D, Taiana E, Neri A.

Oncotarget. 2017 Apr 20;8(36):60605-60623

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D’Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D’Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S.

Cancer Cell. 2017 Jul 10;32(1):88-100.e6

Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.

Magnani L, Frigè G, Gadaleta RM, Corleone G, Fabris S, Kempe MH, Vershure PJ, Barozzi I, Vircillo V, Hong SP, Perone Y, Saini M, Trumpp A, Viale G, Neri A, Ali S, Colleoni MA, Pruneri G, Minucci S.

Nat Genet. 2017 May 26;49(6):970

Utilizing next-generation sequencing in the management of multiple myeloma.

Lionetti M, Neri A.

Expert Rev Mol Diagn. 2017 Jul;17(7):653-663

Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.

Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A, Uccello G, Petrungaro A, Ronco F, Raponi S, Nanni M, Neri A, Ferrarini M, Guarini AR, Foà R, Gentile M.

Leuk Res. 2017 Jun;57:65-71

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.

Magnani L, Frige G, Gadaleta RM, Corleone G, Fabris S, Kempe MH, Verschure PJ, Barozzi I, Vircillo V, Hong SP, Perone Y, Saini M, Trumpp A, Viale G, Neri A, Ali S, Colleoni MA, Pruneri G, Minucci S.

Nat Genet. 2017 Mar;49(3):444-450

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Manni S, Carrino M, Manzoni M, Gianesin K, Nunes SC, Costacurta M, Tubi LQ, Macaccaro P, Taiana E, Cabrelle A, Barilà G, Martines A, Zambello R, Bonaldi L, Trentin L, Neri A, Semenzato G, Piazza F.

Oncotarget. 2017 Feb 28;8(9):14604-14619

Clonal evolution in therapy-related neoplasms.

Fabiani E, Falconi G, Fianchi L, Criscuolo M, Ottone T, Cicconi L, Hohaus S, Sica S, Postorino M, Neri A, Lionetti M, Leone G, Lo-Coco F, Voso MT.

Oncotarget. 2017 Feb 14;8(7):12031-12040

Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression.

Barisione G, Fabbi M, Cutrona G, De Cecco L, Zupo S, Leitinger B, Gentile M, Manzoni M, Neri A, Morabito F, Ferrarini M, Ferrini S.

Blood Cancer J. 2017 Jan 6;6(1):e513

IL21R expressing CD14₊CD16₊ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N.

Haematologica. 2017 Apr;102(4):773-784

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, Massara R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini M, Tassone P, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini M.

Leukemia. 2017 Sep;31(9):1894-1904

Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D’Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.

Clin Cancer Res. 2017 Jun 1;23(11):2891-2904

Targeting Notch as a Therapeutic Approach for Human Malignancies.

Platonova N, Lesma E, Basile A, Bignotto M, Garavelli S, Palano MT, Moschini A, Neri A, Colombo M, Chiaramonte R.

Curr Pharm Des. 2017;23(1):108-134

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Marchica V, Accardi F, Storti P, Mancini C, Martella E, Dalla Palma B, Bolzoni M, Todoerti K, Marcatti M, Schifano C, Bonomini S, Sammarelli G, Neri A, Ponzoni M, Aversa F, Giuliani N.

Int J Hematol. 2017 Jan;105(1):104-108

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).

Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, Monaco F, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Visco C, Calabrese M, Limberti G, Levis A, Contino L, Ciccone G, Ladetto M.

Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895. [Epub ahead of print]

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.

Bari A, Marcheselli R, Marcheselli L, Alvarez I, Pozzi S, Ferri P, Lazzaro A, Fragasso A, Neri S, Baldini L, Carella AM, Angrilli F, Guariglia R, Buda G, Stelitano C, Sacchi S; Gruppo Italiano Studio Linfomi (GISL).

Acta Haematol. 2017;137(1):7-14

Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.

Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Pozzi S, Ferrari A, Baldini L, Gobbi P, Aviv A, Pugliese G, Federico M, Polliack A, Sacchi S.

Hematol Oncol. 2017 Dec;35(4):561-566

Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report.

Pagano L, Dragonetti G, Cattaneo C, Marchesi F, Veggia B, Busca A, Candoni A, Prezioso L, Criscuolo M, Cesaro S, Delia M, Fanci R, Stanzani M, Ferrari A, Martino B, Melillo L, Nadali G, Simonetti E, Ballanti S, Picardi M, Castagnola C, Decembrino N, Gazzola M, Fracchiolla NS, Mancini V, Nosari A, Principe MID, Aversa F, Tumbarello M; SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia).

Haematologica. 2017 Oct;102(10):e407-e410. doi: 10.3324/haematol.2017.172536. Epub 2017 Jul 20

Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia.

Fusco N, Bonometti A, Augello C, Fabris S, Boiocchi L, Fiori S, Morotti D, Fracchiolla N, Berti E, Gianelli U.

Histopathology. 2017 May;70(6):1000-1008

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935

Waldenstrom macroglobulinemia presenting as a bilateral subdural chronic hematoma.

Franzini A, Gribaudi G, Pirola E, Pluderi M, Goldaniga MC, Marfia G, Rampini PM.

J Clin Neurosci. 2017 Jun;40:89-91

The possible role of burden of therapy on the risk of myeloma extramedullary spread.

Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, Cartia CS, Cazzola M, Corso A.

Ann Hematol. 2017 Jan;96(1):73-80